%0 Journal Article
%T Predictors for eltrombopag response in patients with hepatitis C virus-associated thrombocytopenia
%A Heba Elashry
%A Mohamed A Elsebaey
%A Samah A Elshweikh
%A Sherief Abd-Elsalam
%A Tamer A Elbedewy
%J Archive of "Therapeutics and Clinical Risk Management".
%D 2019
%R 10.2147/TCRM.S186106
%X Thrombocytopenia is a common hematological abnormality observed in patients infected with hepatitis C virus (HCV). The use of eltrombopag has been approved for HCV-associated thrombocytopenia. This is the first study aiming to determine the predictive factors of response to eltrombopag therapy in patients with HCV-associated thrombocytopenia
%K HCV
%K therapy
%K thrombocytopenia
%K predictors
%K splenectomy
%K direct-acting antivirals
%K DAAs
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6375108/